A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...

A compelling new study is building on a growing body of evidence showing a common exercise supplement used to build muscle ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.